Haloperidol Richter (Haloperidol)

Haloperidol Richter is indicated for the management of several psychiatric disorders where dopamine blockade is therapeutic.

• Schizophrenia, including acute exacerbations and maintenance therapy.
• Acute psychotic episodes associated with mood disorders or substance use.
• Tourette syndrome, particularly for reduction of motor and vocal tics.
• Severe agitation or aggression in a hospital setting when rapid control is needed.
• Short‑term control of delirium‑related psychosis in medically ill patients.
• Adjunctive treatment in resistant cases where other antipsychotics have been ineffective.

Side effects of Haloperidol Richter vary in frequency; some are relatively common while others are less frequent but may require medical attention.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, especially with long‑term use.
• Significant cardiac arrhythmias, including QT prolongation.

When prescribing Haloperidol Richter, clinicians should evaluate patient history and monitor for conditions that could increase risk of adverse outcomes.

• Assess for cardiovascular disease, as haloperidol can affect heart rhythm.
• Use caution in patients with a history of seizures or epilepsy.
• Evaluate liver and kidney function before initiating therapy.
• Monitor for signs of depression or suicidal thoughts, particularly in younger adults.
• Consider dose adjustments in the elderly due to increased sensitivity.
• Review any history of movement disorders, such as Parkinson’s disease.
• Avoid abrupt discontinuation to reduce risk of withdrawal or rebound psychosis.

Haloperidol Richter may interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk.
• Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants like benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents, which can mask early signs of extrapyramidal symptoms.
• Lithium, as combined use may increase neurotoxic effects.